Your browser is no longer supported. Please, upgrade your browser.
SNY Sanofi daily Stock Chart
Index- P/E24.37 EPS (ttm)2.02 Insider Own16.40% Shs Outstand2.51B Perf Week-0.51%
Market Cap123.16B Forward P/E14.85 EPS next Y3.31 Insider Trans0.00% Shs Float2.29B Perf Month5.93%
Income5.20B PEG2.49 EPS next Q0.76 Inst Own10.60% Short Float0.24% Perf Quarter15.62%
Sales39.61B P/S3.11 EPS this Y1.40% Inst Trans-0.55% Short Ratio3.32 Perf Half Y22.39%
Book/sh24.68 P/B1.99 EPS next Y6.95% ROA- Target Price51.75 Perf Year22.23%
Cash/sh- P/C- EPS next 5Y9.80% ROE- 52W Range36.81 - 50.24 Perf YTD21.54%
Dividend1.58 P/FCF- EPS past 5Y-4.60% ROI6.20% 52W High-2.17% Beta0.90
Dividend %3.21% Quick Ratio- Sales past 5Y-0.20% Gross Margin69.10% 52W Low33.52% ATR0.66
Employees106859 Current Ratio- Sales Q/Q12.20% Oper. Margin21.20% RSI (14)58.72 Volatility0.78% 1.03%
OptionableYes Debt/Eq- EPS Q/Q31.70% Profit Margin27.60% Rel Volume3.15 Prev Close49.07
ShortableYes LT Debt/Eq- EarningsApr 28 BMO Payout38.30% Avg Volume1.66M Price49.15
Recom1.70 SMA201.07% SMA505.91% SMA20017.96% Volume5,230,204 Change0.16%
May-11-17Downgrade Berenberg Buy → Hold
Apr-07-17Downgrade HSBC Securities Hold → Reduce
Apr-06-17Initiated Argus Buy $50
Mar-09-17Initiated Liberum Hold
Nov-07-16Initiated Goldman Neutral
Sep-23-16Initiated Piper Jaffray Neutral
Sep-15-16Resumed JP Morgan Underweight
Sep-13-16Upgrade Exane BNP Paribas Underperform → Neutral
Sep-08-16Upgrade Berenberg Hold → Buy
May-03-16Downgrade HSBC Securities Buy → Hold
Dec-10-15Downgrade Exane BNP Paribas Neutral → Underperform
Dec-01-15Downgrade Morgan Stanley Overweight → Equal-Weight
Nov-09-15Downgrade Bernstein Outperform → Mkt Perform
Oct-15-15Upgrade Morgan Stanley Equal-Weight → Overweight
Apr-22-15Upgrade Citigroup Sell → Neutral
Apr-15-15Initiated Societe Generale Buy
Aug-03-12Downgrade Standpoint Research Buy → Hold
Jan-11-11Downgrade Jefferies Buy → Hold
Nov-16-09Initiated Deutsche Securities Buy
Oct-14-09Upgrade UBS Sell → Neutral
May-24-17 09:06AM  Gardasil and Mercks Vaccines Business in 1Q17 Market Realist
May-23-17 04:25PM  Regeneron, Sanofi Undercut Amgen, AbbVie In Rheumatoid Arthritis Investor's Business Daily
03:08PM  Sanofi Genzyme takes on worlds top-selling drugs with new approval American City Business Journals
10:25AM  Sanofi/Regeneron's Kevzara Gets FDA Approval for Arthritis Zacks
May-22-17 06:35PM  Regeneron, Sanofi rheumatoid arthritis drug wins U.S. approval Reuters
06:05PM  Regeneron, Sanofi rheumatoid arthritis drug wins U.S. approval Reuters
05:47PM  Sanofi and Regeneron Announce FDA Approval of Kevzara® (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients PR Newswire
05:45PM  Regeneron and Sanofi Announce FDA Approval of Kevzara® (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients PR Newswire
04:38PM  Sanofi Wins Favorable CHMP Opinion for Biosimilar Humalog Zacks
02:08PM  Regeneron And Sanofi Have A Near-Term FDA Catalyst Benzinga
09:06AM  Merck vs. Sanofi: Which Stock is a Better Pick Post Q1 Earnings? Zacks
08:15AM  Blog Coverage: CHMP Okays French Pharma Major Sanofi's Insulin Lispro Biosimilar for Treatment of Diabetes Mellitus Accesswire
May-17-17 07:00AM  Bull of the Day: Regeneron (REGN) Zacks
May-16-17 05:42PM  [$$] Big pharma hopes rule change will ease China sales pain Financial Times
May-15-17 08:15AM  Post Earnings Coverage as Merck's EPS Surged 40%; Raised Outlook Accesswire
May-14-17 08:00PM  Henri Termeer, 'giant of biotech' and longtime CEO of Genzyme, dies at 71 American City Business Journals
May-12-17 01:26PM  Sanofi : SNY-US: Dividend Analysis : May 15th, 2017 (record date) : By the numbers : May 12, 2017 Capital Cube
12:04PM  Is Regeneron Pharmaceuticals Stock Still a Buy After Its Big Bounce? Motley Fool
May-11-17 03:49PM  There could a better way to protect against the flu, and it has implications for tackling HIV and the common cold Business Insider
08:30AM  Allegra® Allergy Gears Up for Bike to Work Day Across the U.S. PR Newswire
May-10-17 08:50PM  Another top executive at Sanofi Genzyme leaves company American City Business Journals
04:01PM  Mylan Q1 Revenue Falls Short Of Views As EpiPen Sales Decline Investor's Business Daily
12:20PM  Sanofi: Annual General Shareholders' Meeting of May 10, 2017 GlobeNewswire
11:38AM  Sanofi says has no "absolute need" to do acquisitions Reuters
May-09-17 10:33AM  Sanofi pegs U.S. drug price rises to below healthcare inflation Reuters
08:46AM  Sanofi pegs U.S. drug price rises to below healthcare inflation Reuters
07:57AM  Sanofi pegs U.S. price increases to below healthcare inflation Reuters
07:02AM  A giant drugmaker just set the strictest price-increase caps of the industry Business Insider
May-04-17 05:50PM  Regeneron Shares Rise After Reporting Better-Than-Expected Sales
03:33PM  Regeneron (REGN) Q1 Earnings Miss, Revenues Beat Estimates Zacks
May-02-17 08:30AM  Survey Results Show Eighty Percent of Rheumatoid Arthritis Patients Report Life-Altering Pain Daily or Multiple Times a Week, Despite Treatment PR Newswire
May-01-17 04:53PM  Did Regeneron, Sanofi Just Launch A Blockbuster Drug? Investor's Business Daily
03:53PM  Sarepta Therapeutics May Attract Activist Attention
01:45PM  Regeneron: This Could Be Good
12:57PM  How Much Would Sarepta Therapeutics Fetch in a Buyout? Motley Fool
08:38AM  6 FDA Events to Watch Out for in May 2017 Zacks
08:00AM  Sanofi Genzyme Announces Approval of Cerdelga (eliglustat capsules) by Health Canada for Rare Genetic Condition CNW Group
07:30AM  Today's Research Reports on Trending Tickers: Sanofi and Sarepta Therapeutics Accesswire
Apr-30-17 11:41AM  5 Big Drugmakers With Important Catalysts in May Motley Fool
Apr-29-17 08:03AM  Is Regeneron (Finally) Getting Back on Track? Motley Fool
Apr-28-17 05:46PM  Regeneron (REGN) to Post Q1 Earnings: What's in the Cards? Zacks
11:49AM  [$$] Sanofi 1Q Net Profit Rises on Sale of Animal-Health Unit The Wall Street Journal
11:00AM  Sarepta shares jump as CEOs planned exit spurs takeover speculation American City Business Journals
10:43AM  Sanofi beats 1Q profit forecasts Associated Press
10:16AM  Yes, Sarepta Reported EarningsBut That's Not Why It's Flying Today
09:19AM  Sanofi (SNY) Q1 Earnings Top, Sales Rise Y/Y, Shares Up Zacks
08:34AM  Sarepta CEO Exits Along With a Sanofi Director, So Let's Speculate About a Possible Deal
07:30AM  Sanofi Delivers Robust Q1 2017 Financial Results PR Newswire
05:55AM  Sanofi Shares Hit 18-Month High As Genzyme and Consumer Goods Deliver Strong Q1
02:59AM  Genzyme, CHC lift Sanofi's first-quarter figures, upbeat on Dupixent Reuters
01:37AM  Genzyme, CHC lift Sanofi's first-quarter figures, upbeat on Dupixent Reuters
01:00AM  Regeneron and Sanofi Announce Kevzara® (sarilumab) Biologics License Application Resubmission Accepted for Review by U.S. FDA PR Newswire
Apr-27-17 09:21AM  Amgen's Q1 Results Highlight the Need for an Acquisition Motley Fool
09:08AM  Dupixent Expected to Be a Solid Addition to Regenerons Portfolio Market Realist
Apr-26-17 11:01PM  One in 7 people in Nevada is living with diabetes, and the state is now pushing a new approach to tackle the cost of treatment Business Insider
05:28PM  Amgen Trips Amid Rivals: Sales Miss By $100 Million, But Earnings Top Investor's Business Daily
01:35PM  Will Amgen's Rivals Pop On Its Cholesterol-Busting Drug? Investor's Business Daily
11:39AM  Why Flexion Therapeutics Inc. Stock Is Tanking Motley Fool
04:21AM  Moody's: Outlook for global pharmaceuticals industry stable on low earnings growth, new product launches Moody's
Apr-25-17 10:47AM  K-Mart to Sell Cheaper EpiPen Alternative
08:30AM  New Data Suggest Positive Effects of Sanofi Genzymes Aubagio® (teriflunomide) on Cortical Gray Matter Atrophy Business Wire
08:00AM  Sanofi and Regeneron Announce FDA Approval of a New Once-Monthly Dosing Option for Praluent® (alirocumab) Injection PR Newswire
08:00AM  Regeneron and Sanofi Announce FDA Approval of a New Once-Monthly Dosing Option for Praluent® (alirocumab) Injection PR Newswire
08:00AM  New Investigational Data on Six-Year Efficacy of Sanofi Genzymes Lemtrada® (alemtuzumab) in Multiple Sclerosis Patients Who Experienced Relapse Between Treatment Courses To Be Presented at AAN Business Wire
Apr-24-17 12:54PM  Mylan Tried to Squelch EpiPen Rival, Sanofi Says in Lawsuit Bloomberg
12:21PM  Sanofi Sues Mylan Over EpiPen Practices
12:10PM  Sanofi files U.S. antitrust lawsuit against Mylan over EpiPen Reuters
12:02PM  Sanofi has filed an antitrust suit against Mylan alleging 'illegal conduct' to prevent EpiPen competition MarketWatch
11:21AM  Sanofi files U.S. antitrust lawsuit against Mylan over EpiPen Reuters
08:30AM  Sanofi Receives FDA Approval of Thymoglobulin® for the Prevention of Acute Kidney Transplant Rejection PR Newswire
01:00AM  Regeneron and Sanofi Receive Positive CHMP Opinion for Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis PR Newswire
Apr-21-17 04:15PM  Amgen Trumps Regeneron, Sanofi In Cholesterol Drug Sales Investor's Business Daily
02:22PM  EMA panel recommends nod for Sanofi, Regeneron's arthritis drug Reuters
Apr-20-17 12:50PM  Regulator links Sanofi epilepsy drug to child deformities Reuters
10:45AM  [$$] Sanofi epilepsy drug caused birth defects in up to 4,100 children Financial Times
10:43AM  Sanofi Epilepsy Drug Responsible for Birth Defects in 4,100 Children, French Regulator Says
10:21AM  Eli Lilly (LLY) to Report Q1 Earnings: What's in the Cards? Zacks
09:31AM  Sanofi Genzyme hit with patent lawsuit over new eczema drug American City Business Journals
07:14AM  Sanofi says could buy device assets to boost diabetes Reuters
Apr-19-17 04:17PM  Is J&J's Pharma Sales Slowdown a Warning for Other Players? Zacks
12:25PM  Why Flexion Therapeutics' New Pain Drug Could Be a Game-Changer Motley Fool
07:45AM  [$$] Actis-backed MediS Group Acquires Winthrop Pharma Senegal The Wall Street Journal
Apr-18-17 04:36PM  Could Lilly Outperform These Bigger Rivals On Strong Diabetes Meds? Investor's Business Daily
01:55PM  After Johnson & Johnson Earnings, Buy These Pharma Stocks Zacks
06:00AM  The 7 Most Expensive Prescription Drugs in the World Motley Fool
Apr-17-17 08:30PM  5 Stocks To Profit From The Canadian Marijuana Boom
09:40AM  Lilly and Incyte's Loss Is AbbVie and Regeneron's Gain Motley Fool
Apr-12-17 08:21AM  5 Reasons Why Sanofi (SNY) is a Good Stock to Buy Now Zacks
Apr-11-17 04:24PM  Generics Set To Weaken This Drugmaker; Can MS Drugs Save It? Investor's Business Daily
11:45AM  Boston biotech Rhythm elevates Genzyme head Meeker to board chairman American City Business Journals
10:45AM  Geron Stock Rises after Positive Interim Update on Imetelstat Zacks
09:17AM  Forget Novartis, Buy These Two Pharma Stocks Instead Zacks
Apr-10-17 04:22PM  Is MannKind Corporation Getting Ready to Sell? Motley Fool
10:53AM  Does Incyte Have The Best Cancer Portfolio Among Mid-Cap Biotechs?
Apr-07-17 02:53PM  Sanofi Downgraded at HSBC Securities
12:40PM  Sanofi Genzyme exec jumps to Flexion amid buyout rumors American City Business Journals
10:42AM  Sanofi Buying Flexion: A Smart Move? Motley Fool
Apr-06-17 04:31PM  Boehringer Ingelheim will double down on animal health American City Business Journals
01:08PM  Sanofi May Now Have Moved Past Its Most Challenging Period, Analyst Initiates At Buy Benzinga
Apr-05-17 09:35AM  David Meeker, longtime head of Sanofi Genzyme, to leave company after 23 years American City Business Journals
Sanofi researches, develops, manufactures, and markets therapeutic solutions. The company operates in two segments, Pharmaceuticals and Vaccines. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio, an oral immunomodulatory and Lemtrada, a monoclonal antibody to treat multiple sclerosis. The company also provides Jevtana, a taxane derivative for prostate cancer; Taxotere, a taxoid for various cancers; Eloxatin, a platinum agent for colorectal cancer; Thymoglobulin, a immunosuppressive and immunomodulating agent; Mozobil, a hematopoietic stem cell mobilizer for hematologic malignancies; and Zaltrap, a protein for metastatic colorectal cancer. In addition, it offers Lantus, Apidra, and Insuman human insulins; Toujeo, an oral sulfonylurea; Lyxumia/Adlyxin, a GLP-1 receptor agonist; and Soliqua 100/33/Suliqua, an insulin glargine and lixisenatide combination to treat diabetes; and Praluent, a cholesterol-lowering drug and Multaq, an anti-arrhythmic drug to treat cardiovascular diseases. Further, the company provides Plavix, an anti-platelet agent for atherothrombotic conditions; Lovenox, a heparin for the prophylaxis and treatment of venous thromboembolism and acute coronary syndrome; Aprovel and CoAprovel anti-hypertensives; Renagel and Renvela oral phosphate binders for patients undergoing dialysis; Synvisc and Synvisc-One viscosupplements for patients with osteoarthritis; Stilnox for treatment of insomnia; and Allegra, an anti-histamine for the treatment of seasonal allergic rhinitis and uncomplicated hives. Additionally, it offers consumer health care products and generic medicines; and pediatric, influenza, adult and adolescent booster, meningitis, and travel and endemic vaccines. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sanofi10% OwnerJan 11Buy369.7187,29832,274,87223,505,694Jan 13 04:15 PM
Sanofi10% OwnerJun 14Buy363.8664,73123,552,85923,418,396Jun 16 05:47 PM